# Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

> **NCT04427293** · PHASE1 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 12 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04427293
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-09
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04427293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04427293, "Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/clinical/NCT04427293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*